Company Filing History:
Years Active: 2014-2016
Title: Jiujiu Yu: Innovator in Monoclonal Antibody Development
Introduction
Jiujiu Yu is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for medical applications.
Latest Patents
Jiujiu Yu's latest patents include the development of a humanized anti-human NKG2A monoclonal antibody. This invention relates to agents that act as non-competitive antagonists of the CD94/NKG2A receptor. Specifically, it involves certain anti-NKG2A antibodies, particularly humanized versions of the murine anti-NKG2A antibody Z199. The patent also outlines methods for producing and utilizing these agents and antibodies.
Career Highlights
Jiujiu Yu is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk emphasizes the importance of innovative therapeutic solutions in the biotechnology sector. His contributions have been instrumental in advancing research and development in monoclonal antibody therapies.
Collaborations
Some of Jiujiu Yu's notable coworkers include Petrus Johannes Louis Spee and Jianhe Chen. Their collaborative efforts have further enhanced the research and development initiatives within their field.
Conclusion
Jiujiu Yu stands out as an influential inventor in the biotechnology industry, particularly in the realm of monoclonal antibodies. His innovative patents and contributions to Novo Nordisk A/S highlight his commitment to advancing medical science.